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We  assessed  potential  toxic  effects  of  the  MAGE-A3  Cancer  Immunotherapeutic  on  female  fertility  and
embryo-fetal,  pre-  and  post-natal  development  in rats  and  on  male  fertility  in  rats  and  monkeys.  Three
groups  of  48 female  (Study  1) or 22  male (Study  2) CD rats  received  5 or 3  injections  of  100  L of
saline,  AS15  immunostimulant,  or MAGE-A3  Cancer  Immunotherapeutic  (MAGE-A3  recombinant  pro-
tein  combined  with  AS15)  at  various  timepoints  pre-  or post-mating.  Male  Cynomolgus  monkeys  (Study
3)  received  8 injections  of 500  L  of  saline  (n = 2)  or  the  MAGE-A3  Cancer  Immunotherapeutic  (n  =  6)ancer immunotherapy
eproductive toxicity
at
onkey
mmunostimulant
every  2 weeks.  Rats  were  sacriﬁced  on gestation  day  20 or lactation  day  25  (Study  1)  or 9 weeks  after
ﬁrst injection  (Study  2) and  monkeys,  3  days  or  8 weeks  after  last  injection.  Injections  were  well toler-
ated.  Female  rat  mating  performance  or  fertility,  pre-  and post-natal  survival,  offspring  development  up
to 25 days  of age, and  male  mating  performance  (rats)  or fertility  parameters  (rats  and  monkeys)  were
unaffected.
© 2015  The  Authors.  Published  by  Elsevier  Inc.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Chemotherapy has been a major approach in the treatment of
ancer since the 1940s. Despite improvements in the survival rates,
onventional chemotherapy has disadvantages, including limited
ure rates and cytotoxicity to healthy cells that can sometimes
esult in severe or potentially life-threatening side effects [1–4].
oreover, chemotherapy predominantly target rapidly dividing
ells such as leukocytes and bone marrow precursors, and is con-
idered immunosuppressive [4,5]. Furthermore, some patients do
ot respond to chemotherapy or develop resistance in the course
f treatment [6,7].
Abbreviations: LOQ, limit of quantiﬁcation; HCD, Historical Control Data.
∗ Corresponding author at: Parc de la Noire Epine, 20 Avenue Fleming, 1300 Wavre,
elgium. Tel.: +32 010 85 6028; fax: +32 010 85 8194.
E-mail address: LAWRENCE.M.SEGAL@GSK.COM (L. Segal).
1 Address: GSK Vaccines, Parc de la Noire Epine, Rue Fleming 20, 1300 Wavre,
elgium (at the time of the study).
ttp://dx.doi.org/10.1016/j.reprotox.2014.12.009
890-6238/© 2015 The Authors. Published by Elsevier Inc. This is an open access article unlicense  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Active cancer immunotherapy, used either alone or in com-
bination with chemotherapy, offers a promising approach. The
goal of cancer immunotherapy is to mobilize the patient’s innate
and adaptive immune systems to mount a response against can-
cer cells. Unlike chemotherapy, cancer immunotherapy more
speciﬁcally targets tumor cells, decreasing the risk of damage to
healthy tissues [4,5]. Although durable remissions of solid tumors
have been obtained with antigen-nonspeciﬁc immunotherapeutic
approaches, such as high-dose interleukin-2 (IL-2) or interferon-,
the associated toxicities or side effects remain high [8–10]. The goal
of antigen-speciﬁc cancer immunotherapy is to elicit a de novo host
immune response against selected tumor antigens using cancer
immunotherapeutics [11–13]. The MAGE-A3 cancer immunother-
apeutic, a therapeutic vaccine, was formulated with AS15,
an immunostimulant containing 3-O-desacyl-4′-monophosphoryl
lipid A (MPL), Quillaja saponaria Molina,  fraction 21 (QS-21) and CpG
in a liposome formulation. MPL  is known to be a TLR4 agonist while
CpG is able to bind to TLR9. CpG is also known to strengthen the
anti-tumor cellular immunity. MPL  and QS-21 act synergistically,
being able to induce cell-mediated immune responses [14].
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The MAGE-A3 antigen represents an interesting target for
mmunotherapy, as it is expressed in various tumor types includ-
ng melanoma and nonsmall cell lung cancer (NSCLC) [15–19]. In
ontrast, the human MAGEA3 is silent in normal adult cells except
n the germ cells of the testis, the trophoblasts of the placenta,
nd, at some stages, in the germ cells of fetal gonads (testis and
vary), where the lack of classical Class I (A, B, and C) and Class II
uman leukocyte antigen (HLA) expression should prevent antigen
resentation [20–24].
Tumor antigens naturally trigger only weak spontaneous
mmunological responses, partly due to self-antigen tolerance
25]. In addition, antigens delivered as puriﬁed recombinant pro-
eins are known to be poorly immunogenic and they need to
e combined with immunostimulants to increase the magnitude
f the response. MAGE-A3 Cancer Immunotherapeutic, contain-
ng the MAGE-A3 recombinant protein combined with the GSK
roprietary immunostimulant AS15, is in Phase III clinical trials
onducted by GSK for the treatment of MAGE-A3-expressing NSCLC
MAGRIT, NCT00480025) and melanoma (DERMA, NCT00796445).
he results of the Phase II trials have been previously published
19,26].
Although cancer predominantly affects the elderly, a consider-
ble proportion of patients is diagnosed at a younger age and may
till wish to establish their families [27]. As survival rates follow-
ng cancer treatment continue to improve, preservation of fertility
as become an important issue for both the survivors and clini-
ians involved in cancer care. While it is well documented that
hemotherapy drugs may  cause male and female gonadal damage
r dysfunction and infertility [28–30], little is known about poten-
ial toxic effects of active cancer immunotherapies. Indeed, given
hat MAGEA3 is expressed in the testis, placenta, and at some stages
n germ cells of embryonic gonads, assessment of the potential
ffects of repeated injections of MAGE-A3 Cancer Immunother-
peutic on embryo-fetal, pre- and post-natal development, and
ertility is particularly important.
In support of the clinical development of MAGE-A3 Cancer
mmunotherapeutic, we performed nonclinical safety studies eval-
ating potential toxicity of MAGE-A3 Cancer Immunotherapeutic
o reproduction in two experimental animal models. Following the
uropean Medicines Agency (EMA), U.S. Food and Drug Adminis-
ration (FDA) and World Health Organization (WHO) guidelines
31–34], we evaluated potential toxic effects of MAGE-A3 Can-
er Immunotherapeutic on female fertility and embryo-fetal and
re- and post-natal development in rats (Study 1), on male fertil-
ty in rats (Study 2) and on male fertility endpoints in Cynomolgus
onkeys (Study 3). The rat was chosen as the test species because of
he requirements for a rodent species by regulatory agencies, and
s the most widely used species for pre- and post-natal develop-
ental toxicity assessments. In this species, the MAGE-A3-related
rotein Exhibits 45% of identity with the human protein (sequence
overage of 83.8%) [35]. The Sprague-Dawley Crl:CD® strain was
hosen as it generally known to exhibit robust immune responses.
he choice of this species was also based on a preliminary pilot
tudy that showed the induction of MAGE-A3-speciﬁc antibodies
n rats after an immunization schedule and dosing (1/5th of the
uman dose) of the adjuvanted MAGE-A3 cancer immunothera-
eutic similar to the one applied in the reprotoxicity study. In
ddition, Cynomolgus monkey was used as an animal model in
tudy 3 because the monkey MAGE-A3-related protein is highly
omologous (>95% identity) to the human MAGE-A3 protein [35]
nd is expressed in the monkey testis and in cells at the same differ-
ntiation stage as in the human. In addition, the monkey was chosen
s pharmacologically relevant species because it was  demonstrated
n previous studies that this species mounted antibody responses
o MAGE-A3 at clinically meaningful doses [36]. Both species were
roposed and accepted by regulatory authorities.xicology 51 (2015) 90–105 91
2. Materials and methods
2.1. Regulatory considerations and ethical statement
The studies were conducted in compliance with the EMA  ICH
Harmonized Tripartite Guideline for Detection of Toxicity to Repro-
duction for Medicinal Products & Toxicity to Male Fertility [32],
taking into account the FDA requirements for reproductive studies
on vaccines, the Note for guidance on preclinical pharmacologi-
cal and toxicological testing of vaccines (CPMP/SWP/465/95) [33],
WHO  guidelines on Nonclinical Evaluation of Vaccines [34] and the
FDA Guidance for Industry [31].
The studies were conducted in accordance with Good Labora-
tory Practice (GLP) standards, including the UK GLP regulations
(Act 1986) [37], The Organization for Economic Co-operation and
Development (OECD) Principles on Good Laboratory Practice [38],
Directive 2004 of the European Parliament and of the council [39],
Arrêté du 14 mars 2000 relatif aux bonnes pratiques de laboratoire
du Ministère de l’Emploi et de la Solidarité [40], and the Hunting-
don Life Sciences (HLS; Eye, UK; Studies 1 and 2; rats) or CiToxLAB
(Evreux, France; Study 3; monkeys) standard operating procedures.
Each laboratory had AAALAC accreditation and an in-house Ethical
Review Panel (ERP). The CiToxLAB Ethical Committee reviewed the
study plan before the initiation of the study in monkeys. For studies
1 and 2 in rats, the HLS ERP reviewed the Project License Proto-
col to ensure that the procedures stated within the Project License
comply with regulatory guideline requirements.
2.2. Study design
Studies were conducted under GLP conditions at the HLS labo-
ratories (Studies 1 and 2) or at the CiToxLAB laboratories (Study 3).
Serology evaluations were performed under non-GLP conditions at
GSK laboratories (Rixensart, Belgium).
In Study 1, 144 of 156 (16 rats with body weight below the
range speciﬁed in the protocol were discarded) female rats were
allocated to three groups (1:1:1) of 48 rats that received an initial
intramuscular (IM) injection of 100 L of saline (control group),
AS15 immunostimulant (AS15 group), or the MAGE-A3 Cancer
Immunotherapeutic (MAGE-A3 recombinant protein combined
with the AS15 immunostimulant; MAGE-A3 Cancer Immunothera-
peutic group) 28 days before pairing (initial injection) (Fig. 1A). The
dosing regimen was  established based on the results from a prelim-
inary pilot study which showed that following the administration of
a single dose of 1/5th (100 L) of the human dose of MAGE-A3 Can-
cer Immunotherapeutic at day −28 before mating, seroconversion
occurred at day −5 before mating. Forty-four females from each
group with positive signs of mating were retained and received
additional injections on days 6, 8, 11 and 15 after mating; the
remaining rats were killed six days after pairing/separation. Of the
44 rats retained in each group, 22 were killed on gestation day 20
(embryo-fetal phase) and the remaining 22 animals were allowed
to rear their young to day 25 of age (littering phase) (Fig. 1A). The
offspring did not receive any injections.
In Study 2, 147 rats, 74 males and 73 females, were weighed and
divided into body weight strata (5 g range); 132 sexually mature
rats, 66 males and 66 females, were allocated to three groups
(1:1:1) of 44 rats (each comprising 22 males and 22 females),
by selecting animals from each body weight range in rotation,
after animals with atypical body weight had been discarded. This
procedure ensured that all groups contained populations of rats
with similar initial mean and range of body weights. To cover the
whole period of spermatogenesis, male rats received IM injections
of 100 L of saline (control group), AS15 (AS15 group) or MAGE-
A3 Cancer Immunotherapeutic (MAGE-A3 recombinant protein
92 E. Destexhe et al. / Reproductive Toxicology 51 (2015) 90–105
Fig. 1. Study design. (A) Study 1 and (B) Study 2. Control, rats injected with 100 L of saline; AS15, rats injected with 100 L of AS15 immunostimulant; MAGE-A3 Cancer
Immunotherapeutic, rats injected with 100 L of MAGE-A3 recombinant protein combined with AS15; N, total number of rats per group; n, number of rats within the group;
B,  blood sampling; F0, F0 females; F1-p, offspring; F1-f, fetuses; BM, before mating; GD, gestation day; LD, lactation day; AM,  after mating; 9d post-3, 9 days post 3rd injection;
35d  post-3, 35 days post 3rd injection (termination). The arrows indicate the timepoints at which rats received the injections of saline, AS15 immunostimulant or MAGE-A3
Cancer Immunotherapeutic.
a Females were untreated.
b Males only.
tive Toxicology 51 (2015) 90–105 93
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Table 1
Injection sites and schedule in Study 3 (monkeys).
Site Day
1a 15 29 43 57 71 85 99
1: Right biceps brachiiS x
2:  Left biceps brachiiR x x
3: Left front thighR x x
4:  Left back thighR x x
5:  Right front thighS xE. Destexhe et al. / Reproduc
ombined with the AS15 immunostimulant; MAGE-A3 Cancer
mmunotherapeutic group) on days 42, 28 and 14 before pairing;
emales were not treated. After the treatment period, males were
aired on a one-to-one basis with untreated females for a period
f up to three weeks. Females were sacriﬁced 14 days after mating,
nd males at least nine weeks after the ﬁrst injection (Fig. 1B).
In Study 3, eight of nine sexually mature male monkeys were
elected for the study, based on clinical and laboratory exam-
nations, and manually allocated randomly to two groups that
eceived an IM injection of 500 L of saline (n = 2; control group)
r MAGE-A3 Cancer Immunotherapeutic (n = 6; MAGE-A3 recombi-
ant protein combined with the AS15 immunostimulant; MAGE-A3
ancer Immunotherapeutic group) every two weeks, with a total of
 injections. One monkey from the control group and four from the
AGE-A3 Cancer Immunotherapeutic group (early sacriﬁce group
nimals) were sacriﬁced three days after the last injection (day
02); the remaining monkeys (one control, two  MAGE-A3 Cancer
mmunotherapeutic; recovery group animals) were sacriﬁced after
n eight-week treatment-free period.
.3. Study objectives
The studies assessed potential toxic effects of the injections
f MAGE-A3 Cancer Immunotherapeutic on female CD rat fertil-
ty and embryo-fetal, pre-natal and early post-natal development
Study 1), male fertility and early embryonic development in CD
ats (Study 2), and male fertility endpoints in Cynomolgus monkeys
Study 3; reversibility of potential toxic effects over a period of
ight weeks after the last injection was also assessed). In addition,
mmune responses (serology) to MAGE-A3 Cancer Immunothera-
eutic were evaluated under non-GLP conditions in all studies.
.4. Test items
One dose of the MAGE-A3 Cancer Immunotherapeutic consisted
f 300 g recombinant MAGE-A3 antigen (ProteinD-MAGE-A3-His;
ecMAGE-A3) [41] and a ﬁxed dose of the AS15 immunostimulant,
ontaining MPL  (GSK Vaccines, Rixensart, Belgium), QS-21 (Anti-
enics Inc, a wholly owned subsidiary of Agenus Inc., Lexington,
A,  USA), CpG 7909 synthetic oligodeoxynucleotides containing
nmethylated CpG motifs, and liposome (50 g MPL, 50 g QS-
1 and 420 g CpG 7909). The control was a 0.9% sterile sodium
hloride solution (saline).
.5. Treatment and administration
In all studies, the IM route was selected to mimic  the intended
oute of administration in human therapeutic use.
Rats received 100 l injections of saline, AS15, or the MAGE-A3
ancer Immunotherapeutic (MAGE-A3 recombinant protein com-
ined with AS15) administered in the anterior left or right thigh
uscle. Each dose of the MAGE-A3 Cancer Immunotherapeutic cor-
esponded to 1/5th of the human dose (500 L), considered to be
he maximal volume to be given as a single IM injection to a rat,
epresenting an over-exposure of approximately 50–70 times the
evels that humans are exposed to in a single dose, based on a
0–70 kg human and 170–250 g rat.
Monkeys received 500 l injections of saline or the MAGE-A3
ancer Immunotherapeutic. Each dose of the MAGE-A3 Cancer
mmunotherapeutic corresponded to a full human dose and rep-
esented approximately 10- to 20-fold the human dose relative to
he body weight, based on a 70 kg human and a 3.5–7.5 kg monkey.
njections were administered in different muscles at the different
imepoints, whereby some muscles received only a single injection
nd others up to two injections (Table 1), allowing for evaluation ofS, single injection site; R, repeated injection site.
a First injection.
the appearance of lesions over time and comparison between sites
receiving one or two  injections.
2.6. Experimental animals, housing and husbandry
2.6.1. Studies in rats
Crl:CD® Sprague-Dawley (SD) IGS BR rats were received from
Charles River Laboratories (UK).
In Study 1, female rats were approximately 7 weeks old and
with weights ranging from 167 to 231 g at the study start, and
were 11–12 weeks old at the time of mating. Six days after mat-
ing, females allocated to treatment during gestation weighed from
257 to 378 g.
In Study 2, male rats were approximately 8–9 weeks old at the
study start and had weights ranging from 276 to 300 g, while the
untreated female rats were approximately 10–11 weeks old with
body weights ranging from 226 to 250 g. The males allocated to the
study groups were approximately 9–10 weeks old and had weights
ranging from 332 to 400 g, and the females on gestation day 0 were
approximately 11–12 weeks old with body weights ranging from
239 to 280 g.
The housing conditions were previously described [42]. Brieﬂy,
the rats were allowed free access to a standard rodent diet with no
added antibiotic or other chemotherapeutic or prophylactic agent.
2.6.2. Study 3 (monkeys)
Nine male, purpose-bred Cynomolgus monkeys (Macaca fascic-
ularis) were received from Noveprim Europe (Ebene, Mauritius).
At the study start, monkeys allocated to the study were 43–51
months old with a mean body weight of 5.4 kg, considered as
sexually mature (based on testicular volume, semen sampling,
and testosterone serum levels). During the study period, monkeys
were housed in individual stainless steel cages, at 22 (±3) ◦C
with relative 50% (±30%) humidity in a 12 h/12 h light/dark cycle.
Monkeys received approximately 180 g/day of OWM  (E) SQC  SHORT
expanded diet (Dietex France, SDS, Saint Gratien, France) and a daily
fruit supplement. All monkeys had free access to tap water.
2.7. Clinical signs
Rats were inspected visually at least twice daily for signs of
ill-health or reaction to treatment. In addition, a more detailed
physical assessment of general health was  performed on each rat in
Study 1 weekly before pairing, on days 0, 7, 14 and 20 after mating,
and on days 1, 7, 14, 21 and 25 of lactation, and in Study 2, weekly
on males, and on days 0, 7 and 14 after mating on females. Local
reactions at the injection sites were assessed for four days follow-
ing each injection, then weekly, on day 0 of gestation (Study 1 only)
and at termination.
Monkeys were assessed for mortality, morbidity and clinical
signs twice a day.
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.8. Body weight
In Study 1, body weight of each F0 female rat was recorded on the
rst day of treatment (day −28), weekly until mating was  detected,
n days 0, 3, 6, 8, 11, 15, 17 and 20 after mating, and on days 1, 4,
, 11, 14, 18, 21 and 25 of lactation.
In Study 2, male rats were weighed at the beginning of the study
nd twice weekly until termination. Females were weighed on days
, 4, 7, 11 and 14 after mating.
In Study 3, the body weight of each monkey was recorded twice
efore the beginning of the treatment period, on the ﬁrst day of
reatment and once a week until the end of the study, except in
eeks 13 and 22, when the body weight was recorded twice a week,
nd in week 14, when the body weight was not recorded.
.9. Food consumption
In Study 1, food consumption was recorded for the following
eriods: weekly before pairing, days 0–2, 3–5, 6–7, 8–10, 11–14,
5–16 and 17–19 after mating, and days 1–3, 4–6, 7–10, 11–13,
4–17, 18–20 and 21–24 of lactation. The mean daily consumption
g/rat/day) was calculated for each animal.
In Study 2, food consumption was recorded twice weekly from
he start of treatment until the animals were paired for mat-
ng. From these records, the mean daily consumption per animal
g/rat/day) was calculated for each phase and for each cage.
In Study 3, the amount of food consumed by each monkey was
hecked daily over 21 days before the beginning of the treatment
eriod and then throughout the study.
.10. Mating (studies in rats)
Females were paired on a one-to-one basis on day 28 after the
re-mating injection in Study 1 and 42 days following the ﬁrst pre-
airing immunization in males, for a period of up to 3 weeks in
tudy 2. In both studies, during the mating period, 1 male and 1
emale rat were housed together per cage. Each morning following
airing, the trays beneath the cages were checked for ejected cop-
lation plugs and a vaginal smear was prepared from each female
nd examined for the presence of spermatozoa and the stage of
he estrous cycle. The day on which mating was detected was  des-
gnated day 0 of gestation. Once mating occurred, the males and
emales were separated and smearing was discontinued. The mat-
ng percentage and conception rate were assessed later.
.11. Cesarean section, uterine/ovary evaluations and fetal
xaminations
In Study 1, six days after mating, or after the required number of
ats was allocated to gestation, four rats per group were sacriﬁced.
f the 44 rats in each group, 22 per group (21 in the AS15 group; one
ead female) were sacriﬁced on day 20 after mating. Fetuses were
acriﬁced by chilling on a cold plate. For females allowed to litter,
he litter size was standardized to ten on day 4 of age by randomized
ulling. The females and the remaining offspring were sacriﬁced on
ay 25 of lactation. All adult rats and all offspring aged ≥14 days
ere sacriﬁced by CO2 asphyxiation, while offspring aged <14 days
ere sacriﬁced by intraperitoneal injection of sodium pentobar-
itone. Four-day-old offspring selected for blood sampling were
acriﬁced by decapitation. Macroscopic pathology examinations of
he females, fetuses, and offspring were performed as previously
escribed [42].For each female, the number of corpora lutea in each ovary and
he number of implantation sites, the number and distribution of
esorption sites and live and dead fetuses were recorded for each
terine horn. All fetuses and placentae were dissected from thexicology 51 (2015) 90–105
uterus and weighed individually. Fetuses were individually identi-
ﬁed within the litter, using a coding system based on their position
in the uterus. Each fetus and placenta was externally examined and
any abnormalities were recorded. In addition, the sex of each fetus
was recorded. The fetuses received a fresh external examination,
and were assessed internally post-ﬁxation. Approximately half of
the fetuses in each litter were subject to gross internal examination
of the viscera of the neck, thorax and abdominal cavities. These
fetuses were then eviscerated and their skeletons were ﬁxed in
Industrial Methylated Spirit, prior to processing and staining with
Alizarin Red. The stained fetuses were assessed for skeletal devel-
opment and abnormalities. The remaining fetuses were ﬁxed whole
in Bouin’s ﬂuid, then free-hand serial sections were prepared and
examined under the microscope and visceral abnormalities were
assessed. Normally rare abnormalities which were deﬁnitely detri-
mental to normal subsequent development or could even be lethal,
such as ventricular septal defects, were deﬁned as major abnormal-
ities. Minor differences from normal that are detected relatively
frequently or are considered to have little detrimental effect and
may be a transient stage in the development, such as a bipartite
centrum or a dilated ureter, were deﬁned as minor differences.
In Study 2, the untreated females were sacriﬁced on day 14
after mating, and the following reproductive assessments were
made: the number of corpora lutea in each ovary and the number
of implantation sites, the number and distribution of resorption
sites, and the number of live and dead embryos. All adult rats were
sacriﬁced by CO2 asphyxiation and embryos by decapitation.
2.12. Parturition and post-natal observations (Study 1)
Parturition and post-natal observations, and the duration of ges-
tation were evaluated as previously described [42]. From day 20
after mating, females were inspected three times daily for evidence
of parturition. The progress and completion of parturition was
monitored, and numbers of live and dead offspring were recorded
as well as any observed difﬁculties. All litters were examined at
approximately 24 h after birth (day 1 of age), and then daily there-
after. Clinical signs and litter size were recorded daily, the sex ratio
of each litter was  recorded on days 1, 4 and 25 of age, and individual
offspring body weights were recorded on days 1, 4, 7, 11, 14, 18, 21
and 25 of age.
The following pre-weaning reﬂex developmental tests were
performed on each offspring: surface righting (assessed daily from
day 2 of age until achieved), air righting (assessed daily from day 16
until day 21 of age), auditory function (startle response to a sudden
sharp sound, assessed on day 20 of age), and pupillary reﬂex (pupil
closure response of dark adapted eyes to a bright point source of
light, assessed on day 20 of age).
Offspring surviving to day 25 of age were subject to a com-
plete macroscopic examination; any retained tissues were checked
before disposal of the carcass.
2.13. Evaluation of spermatogenesis
In Study 2, immediately after the scheduled sacriﬁce, samples
for sperm analysis (motility, morphology and sperm count) were
taken. Sperm count and motility were analyzed using the Hamilton
Thorne IVOS Computer Assisted sperm Analyzer version 12.3c. The
left vas deferens, epididymides and testes were removed and the
epididymides and testes were weighed.
In Study 3, semen samples were taken by electroejaculation
from all monkeys twice during the pre-treatment period, approx-
imately every three weeks (±three days) during the treatment
period and three times during the treatment-free period using
a constant voltage stimulator (6020 Stimulator, Harvard Appara-
tus) according to a procedure approved by the CIToxLab Ethical
tive To
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ommittee. Monkeys were not anesthetized for this procedure.
amples were microscopically analyzed for the presence, motil-
ty, morphology, and count of spermatozoa. To assess the effects
f the treatment with the MAGE-A3 Cancer Immunotherapeutic on
he gonads and prostate, measurements of the testes and prostate
olume were performed on all monkeys twice during the pre-
reatment period, approximately every three weeks (±three days)
uring the treatment period and three times during the treatment-
ree period. Prior to examination, monkeys were anesthetized by
n IM injection of ketamine hydrochloride (Imalgene® 500, Merial,
rance) in the right calf muscle. The volume of each testis and
f the prostate was measured by ultrasonography. The measure-
ents were performed using a Megas CV probe (ELEKTO GBM,
aval, France).
.14. Blood sampling
In Study 1, blood samples were obtained from the females at
re-treatment, at day −5 (before pairing), at day 20 after mat-
ng (embryo-fetal phase), and day 25 of lactation (littering phase).
amples were collected into plain tubes either from the sublingual
ein or from the retro-orbital sinus. In Study 2, blood samples were
btained from the males at pre-treatment (ﬁve days before pairing)
nd at termination. Samples were collected into plain tubes from
he sublingual vein during the in-life phase and from the retro-
rbital sinus at termination. Each rat was held under isoﬂurane
nesthesia during the sampling procedure.
In Study 3, monkeys were not anesthetized before blood samp-
ing and no prior fasting was required, unless other investigations
ere planned on the same day. For the assessment of serology
arameters, approximately 3 ml  of venous blood were taken from
he cephalic or saphenous vein into a plain tube once during pre-
reatment and on completion of the treatment and treatment-free
eriods. For the assessment of testosterone levels, approximately
 ml  of blood was collected in tubes without anticoagulant in
he morning (usually at 8 a.m.) twice during the pre-treatment
eriod and then once every three weeks (±three days) during the
reatment period. Testosterone levels were assessed using a direct
adioimmunological method (RIA); each analysis was processed in
uplicate.
.15. MAGE-A3-speciﬁc antibody analysis
MAGE-A3-speciﬁc antibodies were measured by enzyme-linked
mmunosorbent assay (ELISA). Individual antibody responses were
easured and reported either individually or as geometric mean
iters (GMTs). In Study 1, the sera of fetuses were analyzed indi-
idually or as a pool. The recMAGE-A3 protein was  used as coating
ntigen for Studies 1 and 2, while a recombinant MAGE-A3 protein
roduced in baculovirus was used for Study 3. The limit of quantiﬁ-
ation (LOQ) of ELISA was the lowest titer calculated in the range of
uantiﬁcation (20–80%). The LOQ was calculated for each plate and
as between 10 and 38 ELISA units (EU)/ml (Study 1), between 22
nd 32 EU/ml (Study 2) or between 287 and 350 EU/ml (Study 3).
 titer value of a sample inferior to the LOQ was ﬁxed at 24 EU/ml
Study 1) or 27 EU/ml (Study 2); these values corresponded to the
verage of the lower and upper LOQ values for each study.
.16. Sacriﬁce
In Study 2, males were sacriﬁced by CO2 asphyxiation at least
ine weeks after the ﬁrst injection, following completion of the
ecropsy of the females.
In Study 3, after completion of the treatment or treatment-free
eriod, after at least 14 h of fasting, monkeys were tranquilized byxicology 51 (2015) 90–105 95
an IM injection of ketamine hydrochloride, anesthetized by an IV
injection of thiopental sodium and sacriﬁced by exsanguination.
2.17. Necropsy; tissue collection, processing and examination
A full macroscopic examination of all tissues was performed
on all adult rats and monkeys. The injection site reactions were
recorded. Abnormalities in the appearance or size of organs and
tissues were recorded and the required tissue samples preserved
in an appropriate ﬁxative.
In Studies 2 and 3, the following organs were weighed:
epididymides, seminal vesicles (rats only), prostate, testes, and
pituitary gland (monkeys only). Bilateral organs were weighed indi-
vidually. In Study 2, the right epididymis and right testis were ﬁxed
in Bouin’s solution prior to transfer to 70% industrial methylated
spirit. The prostate and seminal vesicles were preserved in 10%
neutral buffered formalin. In Study 3, the organs were preserved in
10% buffered formalin (pituitary gland, prostate and seminal vesi-
cles) or in modiﬁed Davidson’s ﬁxative (testes and epididymides).
All collected tissues were embedded in parafﬁn wax, sectioned at
a thickness of approximately 4 microns and stained with hema-
toxylin eosin and Periodic acid Schiff (PAS, testis only). All the
preserved tissues were examined for all animals sacriﬁced on com-
pletion of the treatment period. Microscopic examination of the
testes was performed after the treatment periods in both studies
to evaluate the stages of maturation of the spermatic cells.
2.18. Immunohistochemistry
Immunohistochemistry evaluations of the expression pattern
of the human MAGE-A3 or the monkey and rat MAGE-A3-related
protein in the testes were performed in non-GLP conditions before
the studies reported herein were initiated. Immunohistochemistry
data obtained partly supported the choice of the animal species.
Parafﬁn sections (5 m thick) of the human (obtained from
the National Disease Research Interchange, Philadelphia, US),
Cynomolgus monkey (Noveprim Ltd. – Port Louis, Mauritius) and
Sprague Dawley rat (Charles River Laboratories, Lyon, France)
testes were incubated with a rabbit polyclonal antibody (TA242;
1/1000) raised against the human recMAGE-A3 protein, or with
TA242 pre-incubated with 47 g/ml recMAGE-A3 protein. Anti-
body binding was  detected using a biotinylated anti-rabbit mouse
monoclonal antibody (Sigma) and streptavidin-horseradish conju-
gate (Invitrogen). 3,3′-Diaminobenzidine was used as chromogen
(DAB detection kit, Invitrogen). Slides were counterstained with
Mayer’s Hemalum (Klinipath).
2.19. Statistics (studies in rats)
Statistical analyses were performed where there was indication
of possible meaningful intergroup differences. In Study 1, all sta-
tistical analyses were carried out using the individual animal (or
means in the case of the litter) as the basic experimental unit. For
Study 2, all statistical analyses were carried out separately for males
and females. Data relating to food consumption were analyzed on
a cage basis.
The following sequence of statistical tests was used for body
weight, food consumption, placental, litter and fetal weights,
litter size and survival indices, pre-weaning examinations data,
organ weights, sperm analysis, motility and count: if 75% of the
data (across all groups) were the same value, then a frequency
analysis was applied. Treatment groups were compared using
pairwise Fisher’s Exact tests [43] for each dose group against the
control. If Bartlett’s test for variance homogeneity [44] was  not
signiﬁcant at the 1% level, then treatment groups were compared
using Student’s t-test. If Bartlett’s test was signiﬁcant at the 1%
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Fig. 2. Body weight of female rats in Study 1. Control, rats injected with 100 L of saline; AS15, rats injected with 100 L of AS15 immunostimulant; MAGE-A3 Cancer
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ats  in AS15 and MAGE-A3 Cancer Immunotherapeutic group during gestation; N = 22
roup  during lactation.
evel, logarithmic and square-root transformations were tried. If
artlett’s test was still signiﬁcant, then treatment groups were
ompared using a Wilcoxon rank sum test [45].
Pre- and post-implantation loss and sex ratio were analyzed by
eneralized mixed linear model with binomial errors, a logit link
unction and litter as a random effect [46]. Each treated group was
ompared to control using a Wald Chi-square test.
For resorptions, each treated group was compared to control by
xact Wilcoxon rank sum test [45].
Comparisons between AS15 or MAGE-A3 Cancer Immunother-
peutic groups and the control group were performed for the
ercentage of litters where a speciﬁc abnormality was  detected
Study 1); Fisher’s exact test was used for each of the compari-
on. Overall percentage of fetuses affected by a speciﬁc abnormality
as analyzed also and the analysis provided a similar conclusion.
hese results should be interpreted with caution since multiple
omparisons were made.
For organ weight data (Study 2), analysis of covariance was  ini-
ially performed using terminal body weight as covariate. If the
ithin-group relationship between organ weight and body weight
as signiﬁcant at the 10% level [47], then the treatment com-
arisons were made on adjusted group means in order to allow
or differences in body weight which might inﬂuence the organ
eights.
Due to the small sample size and the high inter-individual
ariability expected for the evaluated parameters, no statistical
nalyses were performed in Study 3.
. Results
.1. Study 1: Effects of MAGE-A3 Cancer Immunotherapeutic on
emale rat fertility, embryo-fetal and pre- and post-natal
evelopment
.1.1. Mortality, clinical observations, body weight and food
onsumption
There was one unexpected death during the study; following
he last injection, one female from the AS15 group was sacriﬁced
or welfare reasons on day 18 of gestation due to swollen areas on
he upper ventral thorax, ventral abdomen and perigenital area.
he swelling of the perigenital region caused displacement of the
agina. Macroscopic examination revealed large, irregular subcu-
aneous masses in the left and right mammary areas extending
round the vaginal and anal openings; the cut-surface revealedN = 48 rats in each group before pairing; N = 44 rats in the control group and N = 42
 the control group and N = 21 rats in AS15 and MAGE-A3 Cancer Immunotherapeutic
ﬁrm, pale nodular tissue. This event was  considered incidental and
unrelated to treatment with AS15, as it occurred in a single female.
In general, routine external examinations during the course of
the study showed no remarkable ﬁndings. Among animals receiv-
ing the MAGE-A3 Cancer Immunotherapeutic, nineteen animals
showed limited use of the left hind limb on Day 2 of the pre-mating
phase. This ﬁnding was considered to be related to the adminis-
tration of the initial immunization, and did not persist. During the
gestation phase, several animals receiving either the MAGE-A3 Can-
cer Immunotherapeutic or AS15 were observed to have a swollen
area on the right sacral region. Two  days following the pre-mating
injection of the MAGE-A3 Cancer Immunotherapeutic, six of 48 rats
had swellings around the injection site that persisted for up to four
days; swelling was  not observed following injections of AS15 alone
or saline. During the gestation phase, swelling around the injection
site and, to a lesser extent, edema, were seen in rats receiving AS15
or the MAGE-A3 Cancer Immunotherapeutic. The number of rats
in which swelling was  recorded was highest 7–18 days after mat-
ing, coinciding with a 1- to 4-day period following each injection.
During the lactation phase, swelling around the injection site was
observed on day 1 of lactation in one control rat and in two rats
from the AS15 group.
There was  no effect of MAGE-A3 Cancer Immunotherapeutic or
AS15 injections on body weight or food consumption during the
study (Fig. 2).
3.1.2. Reproductive assessment
All but one (AS15 group) female allocated to the littering phase
became pregnant. All but one (MAGE-A3 Cancer Immunotherapeu-
tic group) female gave birth to live offspring. There was  no effect
of the treatment with the MAGE-A3 Cancer Immunotherapeutic or
AS15 on the parturition process or on gestation length. Gestational
length was  22–23 days, except for one control female (24 days)
(Table 2).
All females surviving to scheduled termination on day 20 after
mating were pregnant. Maternal treatment with the MAGE-A3
Cancer Immunotherapeutic or AS15 had no effect on the mean
numbers of corpora lutea, implantations, embryo-fetal resorptions,
live young or pre- and post-implantation losses (Table 3). In the
AS15 group, the mean number of male fetuses was  statistically sig-
niﬁcantly lower (6.9 vs 8.9; p<0.01) and the mean number of female
fetuses was statistically signiﬁcantly higher (8.9 vs 7.3; p<0.05)
than in the control group (Table 3). This difference was consid-
ered to have occurred by chance and to be unrelated to treatment,
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Table  2
Mating performance and gestation length (Study 1).
Control AS15 MAGE-A3 Cancer Immunotherapeutic
Number of female rats/cage
Acclimatization period Up to 4 Up to 4 Up to 4
Mating period 1a 1a 1a
Gestation period (up to Day 17 after mating) 1 1 1
Littering period (from Day 17 after mating to Day 25 of lactation) 1 + litter 1 + litter 1 + litter
Number mating, n (%) 47 (98) 48 (100) 47 (98)
Number pregnant, n (%) 47 (100) 47 (98) 45 (96)
Number pregnant killed on Day 20, n (%) 22 (100) 22 (100) 21 (95)
Number littering live pups, n 22 21 21
Gestation length, n (%)
22 days 9 (41) 8 (38) 7 (33)b
22.5 days 6 (27) 7 (33) 7 (33)b
23 days 6 (27) 6 (29) 7 (33)b
23.5 days 0 0 0
24  days 1 (5) 0 0
Control, rats injected with 100 L of saline; AS15, rats injected with 100 L of AS15 immunostimulant; MAGE-A3 Cancer Immunotherapeutic, rats injected with 100 L of
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oAGE-A3 Cancer Immunotherapeutic; n, number of rats; %, percentage.
a Besides 1 female rat per cage 1 male rat was housed in the cage.
b Percentage distribution of gestation lengths calculated from 21 animals (one pr
ecause a similar pattern was not replicated in the subset of litters
llocated to the littering phase, where the mean numbers of male
r female offspring were similar (see Section 3.1.3.). Group mean
alues for placental, litter and fetal weights were similar for all
roups.
The incidence of major abnormalities (including misshapen
ens, cleft palate, membranous ventricular septal defect, malro-
ated heart, inguinal hernia, imperforate anus and bent scapula)
n fetuses was similarly low in all groups, with four of 356
1.1%) affected fetuses in the control group and two of 334
0.6%) affected fetuses in the MAGE-A3 Cancer Immunotherapeu-
ic group (no affected fetuses were reported in the AS15 group).
here was no difference in the fetal and litter incidence of minor
bnormalities in the AS15 and MAGE-A3 Cancer Immunothera-
eutic groups compared to the control group, except for the litter
ncidence of umbilical left artery abnormalities, which was sta-
istically signiﬁcantly higher (p = 0.0485) in the MAGE-A3 Cancer
mmunotherapeutic group than in the control group (Table 4).
owever, this minor visceral ﬁnding was regarded as a normal vari-
tion as the incidence was within the Historical Control Data (HCD)
ange.
able 3
itter data – group mean values for female rats killed on Day 20 of gestation (Study 1).
Control (N = 22) 
Corpora lutea, mean (SD) 18.0 (1.62) 
Implantations, mean (SD) 16.7 (1.70) 
Resorptions, mean 0.5 
Live  young, mean (SD)
Total 16.2 (1.87) 
Male  8.9 (2.44) 
Female 7.3 (2.53) 
Sex  ratio, % male 55.0 
Implantation loss, %
Pre 7.0 
Post 3.3 
Placental weight (g), mean (SD) 0.53 (0.048) 
Fetal weight (g), mean (SD) 3.89 (0.230) 
Male fetal weight (g), mean (SD) 3.97 (0.235) 
Female fetal weight (g), mean (SD) 3.79 (0.240) 
ontrol, rats injected with 100 L of saline; AS15, rats injected with 100 L of AS15 imm
AGE-A3 Cancer Immunotherapeutic; N, number of rats in the group; SD, standard devi
va);  Post, post implantation phase.
* Statistically different value compared to the control group (p < 0.05).
** Statistically different value compared to the control group (p < 0.01).
‡ Statistically different value compared to the AS15 group (p < 0.05).t female failed to litter).
In the AS15 group there was  a slightly higher incidence of
fetuses/litters with the following minor abnormalities compared
with the saline group (Table 2): sutural bone abnormalities, cervi-
cal ribs abnormalities, incomplete ossiﬁcation of cranial centers and
sacrocaudal vertebrae, and ossiﬁed cervical vertebral centra. The
incidence of sutural bone and sacrocaudal vertebrae abnormalities
were within the HCD range. The incidences of ossiﬁed cervical ver-
tebral centra were within the fetal incidence HCD range, but outside
the litter incidence HCD range. The low incidences of fetuses/litters
with cervical ribs abnormalities and incomplete ossiﬁcation of cra-
nial centers were just outside the HCD range. In the MAGE-A3
Cancer Immunotherapeutic group, a number of differences from
the saline group were similar to those recorded in the AS15 group:
there were slightly higher incidences of fetuses/litters with cer-
vical ribs abnormalities and incomplete ossiﬁcation of cervical and
sacrocaudal vertebrae. All the litter incidences were within the HCD
range and were thus regarded as a normal variation.Injections of AS15 or the MAGE-A3 Cancer Immunotherapeutic
did not affect mating performance or fertility. Of the 142 females
that mated, 139 attained pregnancy. Two females, one in the con-
trol group and one in the MAGE-A3 Cancer Immunotherapeutic
AS15 (N = 21) MAGE-A3 Cancer Immunotherapeutic (N = 21)
17.3 (2.35) 17.6 (2.31)
16.5 (2.04) 16.7 (2.58)
0.8 0.8
15.8 (2.34) 15.9 (2.32)
6.9** (2.05) 8.2 (2.07)
8.9* (2.01) 7.7 (2.22)
43.7** 51.9‡
5.8 5.7
4.8 4.3
0.55 (0.071) 0.53 (0.052)
3.90 (0.171) 3.83 (0.215)
4.02 (0.221) 3.90 (0.232)
3.81 (0.157) 3.75 (0.218)
unostimulant; MAGE-A3 Cancer Immunotherapeutic, rats injected with 100 L of
ation; %, percentage; Pre, pre implantation phase (losses due to nonfertilization of
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Table 4
Incidence of minor visceral and skeletal abnormalities in fetuses and litters (Study 1).
Group Fetuses Litters
Control AS15 MAGE-A3 Cancer
Immunotherapeutic
Control AS15 MAGE-A3 Cancer
Immunotherapeutic
Visceral abnormalities
Number of examined rats 179 165 168 22 21 21
Left  umbilical artery, n – 3 4 – 3 4*
Skeletal abnormalities
Number of examined rats 177 166 166 22 21 21
Cervical rib, n 1 5 4 1 5 3
Incomplete ossiﬁcation/unossiﬁed
Cranial centers, n 25 36 24 10 14 12
Sacrocaudal vertebrae, n 6 9 10 4 4 7
Precocious ossiﬁcation
Cervical vertebral centra, n 3 8 1 3 6 1
C 5 imm
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aontrol, rats injected with 100 L of saline; AS15, rats injected with 100 L of AS1
AGE-A3 Cancer Immunotherapeutic; n, number of affected rats.
* Statistically signiﬁcantly higher value as compared to control (Fisher’s exact tes
roup, failed to mate prior to the cessation of pairing; neither
emale showed normal estrous activity during the pairing period.
iven that only two females, one of which was from the control
roup, failed to mate, a relation to treatment with MAGE-A3 Cancer
mmunotherapeutic was excluded.
.1.3. F1 litter responses
There was no effect of maternal treatment with the MAGE-A3
ancer Immunotherapeutic or AS15 on mean implantation counts,
itter size or offspring survival (in-utero or pre-weaning), or body
eight (Table 5). The sex ratio, as assessed by the percentage of
ales and females per litter, was comparable in all groups and in
ine with expectations.
The mean age at attainment for the surface (ability to regain a
ormal upright stance when placed in a supine position) and air
able 5
itter size, offspring survival, body weight and developmental parameters.
Control (N = 22) AS
Implantations, mean (SD) 16.6 (3.5) 17
Total litter size, mean (SD) 15.4 (3.5) 16
Post implantation survival index, % 91.8 95
Live  birth index, % 98.8 98
Preculling viability index % 97.3 99
Postculling viability index, % 95.9 10
Body weight, male/female offspring
Before cull
Day of age 1, mean (SD) 7.3 (0.8)/6.9 (0.7) 7.0
Day  of age 4, mean (SD) 10.4 (1.5)/9.9 (1.3) 9.9
After  cull
Day of age 4, mean (SD) 10.4 (1.4)/10.0 (1.2) 9.9
Day  of age 7, mean (SD) 16.7 (2.0)/15.8 (2.0) 16
Day  of age 11, mean (SD) 26.9 (2.7)/25.9 (3.1) 26
Day  of age 14, mean (SD) 34.8 (2.4)/33.2 (3.0) 34
Day  of age 18, mean (SD) 44.5 (3.5)/42.5 (3.8) 43
Day  of age 21, mean (SD) 56.0 (4.5)/53.5 (4.5) 53
Day  of age 25, mean (SD) 79.1 (5.3)/74.2 (5.0) 76
Pre-weaning examinations
Surface righting
Day of age, mean (SD) 3.6 (0.74) 3.8
Air  righting
Day of age, mean (SD) 17.0 (0.44) 17
Control (N = 210) AS
Pupil  reﬂex, n, (%) pass 210 (100.0) 21
Startle response, n (%) pass 210 (100.0) 21
ontrol, rats injected with 100 L of saline; AS15, rats injected with 100 L of AS15 imm
AGE-A3 Cancer Immunotherapeutic; N, number of tested rats; n, number of affected rats
n  Day 1 after littering/Total number of offspring born) × 100; Preculling viability index (
fter  littering) × 100; Postculling viability index (%) = (Number live offspring on Day 21 af
* Statistically different value compared to the AS15 group (p < 0.05).
** Statistically different value compared to the control group (p < 0.05).unostimulant; MAGE-A3 Cancer Immunotherapeutic, rats injected with 100 L of
.0485).
(ability to fall down on its feet when dropped in a supine position)
righting reﬂexes for offspring was  similar between groups (Table 5).
There was no effect of maternal treatment on the percentage of
offspring showing auditory and pupillary responses on day 20 of
age.
3.1.4. Post-mortem examinations
Macroscopic examination of females at scheduled termination
did not indicate any effect of treatment with either the MAGE-A3
Cancer Immunotherapeutic or AS15.
Of the few offspring that died during the early post-natal period,
most showed an absence of milk in the stomach, which is common
in offspring that die at an early age. There were no signiﬁcant ﬁnd-
ings at post-mortem examination for offspring that survived to the
scheduled termination.
15 (N = 21) MAGE-A3 Cancer Immunotherapeutic (N = 21)
.5 (1.2) 16.4 (2.0)
.8 (1.4) 15.3* (3.1)
.1 93.1
.0 98.4
.4 98.1
0 95.8
 (0.5)/6.5** (0.5) 7.0 (0.6)/6.7 (0.7)
 (0.9)/9.2** (1.0) 10.4 (1.2)/10.0* (1.3)
 (0.9)/9.2** (1.0) 10.4 (1.2)/10.0* (1.3)
.2 (1.0)/15.2 (1.4) 16.9 (2.1)/16.3* (2.0)
.6 (1.6)/25.1 (2.1) 27.2 (2.8)/26.7 (3.0)
.2 (2.1)/32.5 (2.8) 34.6 (3.3)/33.9 (3.4)
.4 (2.9)/41.6 (3.5) 43.8 (4.2)/43.1 (4.4)
.9 (3.5)/51.3 (4.6) 54.0 (7.0)/53.0 (6.2)
.6 (4.6)/71.4 (5.3) 75.9 (9.4)/73.0 (6.9)
 (0.61) 3.5 (0.74)
.0 (0.47) 17.1 (0.99)
15 (N = 210) MAGE-A3 Cancer Immunotherapeutic (N = 194)
0 (100.0) 192 (99.0)
0 (100.0) 194 (100.0)
unostimulant; MAGE-A3 Cancer Immunotherapeutic, rats injected with 100 L of
; %, percentage; SD, standard deviation. Live birth index (%) = (Number live offspring
%) = (Number live offspring on Day 4 before culling/Number live offspring on Day 1
ter culling/Number live offspring on Day 4 after culling) × 100.
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3.1.5. Serology
No recMAGE-A3-speciﬁc antibodies were detected in the sera
of rats before the ﬁrst injection (day −35) except for one of 44
females from the MAGE-A3 Cancer Immunotherapeutic group, in
which a very low titer (75 EU/ml), close to the LOQ, was detected.
No recMAGE-A3-speciﬁc antibodies were detected in the sera of
the dams, fetuses or offspring of the control group (except for one
of 11 fetuses for which a titer of 2886 EU/ml was measured at day
20 of gestation).
In the AS15 group, recMAGE-A3-speciﬁc antibodies were
detected in the dams at only one timepoint (gestation day 20; ﬁve
days after the ﬁfth injection) at which 15 of 21 dams (57%) had
a very low, but measurable GMT, according to the LOQ deﬁnition
used. This GMT  was 500-fold lower compared to the GMT  of rats
following ﬁve injections of MAGE-A3 Cancer Immunotherapeutic
(46 EU/ml vs 29,443 EU/ml) (Supplementary Fig. 1A). This obser-
vation was  transient as recMAGE-A3-speciﬁc antibodies were not
detected 28 days later (at day 25 of lactation; 33 days after the ﬁfth
injection). No recMAGE-A3-speciﬁc antibodies were detected in the
sera of fetuses or offspring from the AS15 group (Supplementary
Fig. 1B and C), with the exception of one of 72 four-day-old off-
spring and two  of 84 25-day-old offspring with very low antibody
levels detected (54, 34 and 66 EU/ml, respectively).
In the MAGE-A3 Cancer Immunotherapeutic group, recMAGE-
A3-speciﬁc antibodies were detected 23 days following the ﬁrst
injection (ﬁve days before mating) in all but one dam, with a GMT
markedly higher as compared to baseline (3014 EU/ml). After ﬁve
injections, recMAGE-A3-speciﬁc antibody titers further increased
in all dams from this group, with GMTs of 29,443 EU/ml at gestation
day 20 (ﬁve days after the ﬁfth injection) and 21,079 EU/ml at day
25 of lactation (33 days after the ﬁfth injection) (Supplementary Fig.
1A). recMAGE-A3-speciﬁc antibodies were also detected in the sera
of fetuses and offspring, with GMTs of 4217 EU/ml  for the fetuses
at gestation day 20, and 7567 EU/ml and 8850 EU/ml, respectively
at four, and 25 days of age for the offspring (Supplementary Fig. 1B
and C).
3.2. Study 2: Effects of MAGE-A3 Cancer Immunotherapeutic on
rat male fertility and early embryonic development
3.2.1. Mortality, clinical observations, body weight and food
consumption
No unscheduled mortalities or signs of ill-health were recorded.
Injections of AS15 or the MAGE-A3 Cancer Immunotherapeutic
were well tolerated.
Injection site reactions, restricted to swollen areas around the
injection site, were generally observed 1–4 days after each injection
of the MAGE-A3 Cancer Immunotherapeutic or AS15.
Following the ﬁrst injection of the MAGE-A3 Cancer
Immunotherapeutic or AS15, mean body weight gain during
the following three days was  slightly but statistically signiﬁcantly
lower in males from these groups than in the control group (mean
values: 15 g in AS15 and 16 g in the MAGE-A3 Cancer Immunother-
apeutic vs 19 g in the control group; p < 0.05). Thereafter, mean
body weight gains were similar to control (Table 6). There were no
intergroup differences in the mean body weight performance of
the untreated females during gestation (data not shown).
There was no effect of the MAGE-A3 Cancer Immunotherapeutic
or AS15 injections on the mean food consumption of the male rats
prior to pairing.3.2.2. Mating performance and fertility
There was no effect of the MAGE-A3 Cancer Immunotherapeutic
or AS15 injections on mating performance or fertility (Table 7). All
males successfully mated within the ﬁrst four days of the pairing
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Table 7
Litter data – group mean values for female rats killed on day 14 of gestation (Study 2).
Number of rats per cage Males Females
Pre-mating period Up to 4 Up to 4
Mating period 1 1
Gestation – Up to 4a
Males after mating Up to 4 –
Control (N = 22) AS15 (N = 22) MAGE-A3 Cancer
Immunotherapeutic (N = 21)b
Mating males, n (%) 22 (100) 22 (100) 22 (100)
Number achieving pregnancy, n (%) 22 (100) 22 (100) 22 (100)
Fertility index, % 100 100 100
Corpora lutea, mean (SD) 16.5 (2.24) 17.1 (1.44) 17.5 (1.71)
Implantations, mean (SD) 15.5 (2.02) 16.0 (2.05) 16.4 (1.80)
Resorptions, mean 1.2 0.5 0.9
Live  embryos, mean (SD) 14.3 (3.40) 15.5 (2.44) 15.6 (2.31)
Implantation loss, %
Pre 5.8 6.0 6.1
Post  8.2 3.6 5.4
Control, rats injected with 100 L of saline; AS15, rats injected with 100 L of AS15 immunostimulant; MAGE-A3 Cancer Immunotherapeutic, rats injected with 100 L of
MAGE-A3 Cancer Immunotherapeutic; N, number of rats in the group; n, number of rats affected; SD, standard deviation; %, percentage; Pre, pre implantation phase (losses
due  to nonfertilization of ova); Post, post implantation phase.
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Ma Females at the same gestation phase.
b The number of rats included in the analyses was N = 21, except for the evaluatio
 = 22.
eriod and all untreated females sustained pregnancy through mid-
estation.
.2.3. Reproductive assessment
There was no effect of treatment of males with the MAGE-
3 Cancer Immunotherapeutic or AS15 on the litter, as assessed
y the mean number of implantations, resorptions, live embryos
nd pre- and post-implantation losses (Table 7). All untreated
emales were pregnant with live embryos on day 14 of gesta-
ion.
There was no effect of treatment with the MAGE-A3 Cancer
mmunotherapeutic or AS15 on sperm motility (Table 8). When
ompared with the control group, treated males showed a marginal
ut statistically signiﬁcant increase in the mean percentage of
otile sperm (94% in the AS15 group and 95% in the MAGE-A3 Can-
er Immunotherapeutic group vs 91% in the control group; p < 0.05).
owever, this difference was partially attributable to one control
ale with a particularly low percentage motile sperm (65%). When
ompared with the historical data range for males of the same strain
nd of a similar age (±two weeks), all mean values for percent-
ge of motile sperm were considered to be within a normal range.
herefore, a relationship to treatment with the MAGE-A3 Cancer
mmunotherapeutic or AS15 was excluded.
able 8
eproductive parameters of male rats given in group mean values (N = 22 for each group)
Control 
Motile sperm, % (SD) 91 (7) 
Progressively motile sperm, % (SD) 56 (13) 
Cauda epididymis
Weight, g (SD) 0.250 (0.024) 
Sperm count, millions/g (SD) 1077 (300) 
Total, million (SD) 268 (79) 
Testis
Weight, g (SD) 1.84 (0.15) 
Sperm  count, millions/g (SD) 174 (52) 
Total,  million (SD) 320 (102) 
ontrol, rats injected with 100 L of saline; AS15, rats injected with 100 L of AS15 imm
AGE-A3 Cancer Immunotherapeutic; SD, standard deviation; %, percentage.
* Statistically different value compared to the control group (p < 0.05).
** Statistically different value compared to the control group (p < 0.01).he mean number of corpora lutea and mating performance and fertility, which was
There was  no effect of treatment with MAGE-A3 Cancer
Immunotherapeutic or AS15 on testis weight, the numbers of
homogenization-resistant spermatids, or the numbers or concen-
tration of spermatozoa in the cauda epididymis.
Microscopic examination did not reveal any effect of treatment
with the MAGE-A3 Cancer Immunotherapeutic or AS15 on sperm
morphology, which was  normal in over 97% of the sperm samples
in each group.
3.2.4. Macropathology and histopathology
Following necropsy, there were no major macroscopic ﬁndings.
There was no effect of the MAGE-A3 Cancer Immunotherapeutic
or AS15 injections on mean weight of the testes, epididymides,
seminal vesicles or prostate.
Microscopic examination of the right testis and epididymis,
prostate and seminal vesicles did not reveal any changes that could
be associated with injections of MAGE-A3 Cancer Immunothera-
peutic or AS15. Evaluation of the seminiferous tubules of the right
testis revealed no cell- or stage-speciﬁc abnormalities.3.2.5. Serology
No recMAGE-A3-speciﬁc antibodies were detected in the sera
of rats from the three groups before the ﬁrst injection or in the
 – Study 2.
AS15 MAGE-A3 Cancer Immunotherapeutic
94* (4) 95** (5)
51 (13) 58 (14)
0.253 (0.023) 0.250 (0.028)
970 (239) 1077 (302)
245 (64) 269 (78)
1.75 (0.14) 1.81 (0.19)
168 (52) 174 (66)
295 (93) 314 (119)
unostimulant; MAGE-A3 Cancer Immunotherapeutic, rats injected with 100 L of
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sera of the control rats at any timepoint. Following the third injec-
tion to rats from the AS15 group, a very low GMT  (31 EU/ml), in
the range of the LOQ, was  detected in eight of 22 rats. In contrast,
following the last injection of MAGE-A3 Cancer Immunotherapeu-
tic, recMAGE-A3-speciﬁc antibody titers were markedly increased
(GMT = 17,075 EU/ml) as compared to baseline, and were still
detected at necropsy (at nine weeks following the ﬁrst injection),
although at lower levels (GMT = 6734 EU/ml) (Supplementary Fig.
2).
3.3. Study 3: Potential toxic effects of the MAGE-A3 Cancer
Immunotherapeutic on the reproductive organs of male monkeys
and reversibility of the potential toxic effects over a
treatment-free period of eight weeks
3.3.1. Mortality, clinical observations and body weight
IM administrations of the MAGE-A3 Cancer Immunotherapeu-
tic were well tolerated and only incidental and unrelated ﬁndings
were observed. There were no serious reactions to treatment and
no mortality. All monkeys maintained or gained body weight over
the period of the study, and food consumption was  unaffected by
treatment with MAGE-A3 Cancer Immunotherapeutic.
3.3.2. Reproductive assessment
Regular monitoring of testicular and prostatic volume (see 2.13),
seminology parameters (see 2.13) and circulating testosterone lev-
els (see 2.14) was conducted throughout the study (during the
treatment and treatment-free periods).
Testicular volume and prostate volume, as estimated by echog-
raphy, showed a tendency to increase slightly over the period of
the study (treatment period and successive treatment-free period).
There was no indication of any effect of treatment with MAGE-A3
Cancer Immunotherapeutic on these parameters.
Sperm count and morphology were unaffected by treatment
with the MAGE-A3 Cancer Immunotherapeutic; sperm motility
was uniformly high in the control and the MAGE-A3 Can-
cer Immunotherapeutic-treated monkeys throughout the study
(Table 9). Occasional sperm samples could not be evaluated due to
sample coagulation or insufﬁcient volume; however, these events
were unrelated to treatment. It was thus concluded that repeated
IM administrations of MAGE-A3 Cancer Immunotherapeutic did
not affect seminological parameters.
Circulating testosterone levels were characterized by substan-
tial variability but there was no indication that treatment with
the MAGE-A3 Cancer Immunotherapeutic had any effect on testos-
terone levels during the treatment or treatment-free periods
(Supplementary Table 1). The observed variations were attributed
to normal physiological ﬂuctuations, i.e. pulsatile secretion of
testosterone in males [48,49].
3.3.3. Pathology ﬁndings
No evidence of treatment-related changes on the weights of
testes, prostate, epididymis or the pituitary gland was  found at the
end of the treatment or treatment-free periods (Table 10). The con-
trol monkey was  the biggest, hence the most mature and therefore
had higher absolute organ weights. However, the relative-to-body
organ weights were close or within the range of those observed in
the vaccinated monkeys. Also, when a careful microscopic exami-
nation was  performed on the testes, no morphological changes in
the association of various germ cell types at a speciﬁc time-point
of development of the seminiferous tubule were observed. Mul-
tinucleated germ cells were sporadically seen in 1 (of 4) treated
monkeys and in the control individual. Atrophy of some seminifer-
ous tubules was recorded in 1 (of 4) treated monkeys. This ﬁnding
was characterized by foci of seminiferous tubules with germ cell
depletion and Sertoli cell vacuolation. As the microscopic ﬁndings
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Table 10
Reproductive organ weights at necropsy (Study 3).
Organ, mean values Controla MAGE-A3 Cancer Immunotherapeutic
K0 (N = 1) R1 (N = 1) K0 (N = 4) R1 (N = 2)
Final body weight, g (SD) 7900.0 5640.0 [4.700–7.420] [5.280–6.400]
Epididymis left
Weight, g (SD) 3.97 3.36 [2.118–2.752] [2.563–3.075]
%  Body (SD) 0.05024 0.05961 [0.037–0.056] [0.040–0.058]
Epididymis right
Weight, g (SD) 4.08 3.06 [2.141–2.930] [2.615–3.066]
%  Body (SD) 0.05166 0.05429 [0.039–0.054] [0.041–0.058]
Pituitary gland
Weight, g (SD) 0.06300 0.06000 [0.059–0.078] [0.055–0.095]
%  Body (SD) 0.00080 0.00106 [0.001–0.002] [0.001–0.002]
Prostate
Weight, g (SD) 3.51 2.53 [2.677–5.358] [2.289–2.476]
%  Body (SD) 0.04441 0.04488 [0.049–0.086] [0.036–0.047]
Testis left
Weight, g (SD) 21.35 16.26 [14.43–19.71] [12.05–17.33]
%  Body (SD) 0.27020 0.28830 [0.264–0.313] [0.188–0.328]
Testis right
Weight, g (SD) 21.04 15.68 [13.831–20.667] [11.717–16.910]
%  Body (SD) 0.26638 0.27801 [0.253–0.332] [0.183–0.320]
Control, monkeys injected with 500 L of saline; MAGE-A3 Cancer Immunotherapeutic, monkeys injected with 500 L of MAGE-A3 Cancer Immunotherapeutic; K0, terminal
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a Due to the limited number of monkeys in the control group, no statistical analy
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onkeys of this age (and were each present in one animal only) a
elationship to treatment was excluded.
In summary, the weights of epididymides, pituitary, prostate
nd testes were found to be unaffected by treatment with MAGE-
3 Cancer Immunotherapeutic. On histopathological evaluation of
he epididymides, pituitary gland, prostate, seminal vesicles and
estes, ﬁndings were limited to those spontaneously observed in
ynomolgus monkeys of this age.
.3.4. Serology
Antibodies speciﬁc for the recombinant MAGE-A3 protein
bacMAGE-A3) were not detected in monkeys included in this study
efore MAGE-A3 Cancer Immunotherapeutic injection or in the
ontrol group at any timepoint.
Three days following the last injection of MAGE-A3 Cancer
mmunotherapeutic, all monkeys (n = 6) demonstrated high MAGE-
3-speciﬁc antibody titers that were still detectable eight weeks
fter the last injection (for the two monkeys evaluated), although
t lower levels (8896 EU/ml and 18,344 EU/ml) than three days after
he last injection (21,088–51,946 EU/ml) (Supplementary Fig. 3).
.4. Detection of MAGE-A3 in the testis
The MAGE-A3 expression pattern was evaluated in the testes
f rats, Cynomolgus monkeys and humans by immunohistochem-
stry using TA242 antibody. A strong staining limited to the germ
ells was observed in all three species as shown in rat (Fig. 3A),
onkey (Fig. 3C), and human (Fig. 3E) testes. However, in the rat,
he staining was observed in cells at a later stage of differentiation
late spermatids) compared to the monkey and the human sam-
les (spermatogoniae and primary spermatocytes). No staining was
bserved when the antibody was pre-incubated with the human
ecMAGE-A3 protein before use (Fig. 3B, D and F), suggesting that
he staining observed in rat and monkey samples was speciﬁc to
he rat or monkey MAGE-A3-related protein. SD, standard deviation; %, percentage.
s performed on the organ weight.
4. Discussion
The MAGE-A3 Cancer Immunotherapeutic is currently under
evaluation in two Phase III clinical trials in patients with NSCLC
or melanoma. As MAGE-A3 is speciﬁcally expressed by tumors, the
risk of mounting an active immune response against normal tis-
sues is considerably reduced. In healthy adult organs, MAGE-A3
expression is only found in the germ cells of the testes and in the
placenta; however, these cells, being devoid of HLA Class I and Class
II molecules, have no antigen presentation capabilities, excluding
the possibility of developing immune-related toxicity [23,24,50].
Moreover, the MAGE-A3 antigen is not expressed at the surface
of the cells, but only in their cytoplasm [51]. As a consequence,
MAGE-A3-speciﬁc antibodies cannot access the antigen directly
and cell killing via an antibody-mediated mechanism, such as the
antibody-dependent cellular cytotoxicity, cannot occur. The MAGE-
A3-speciﬁc T-cells can recognize antigen expressing cells only if
peptides derived from MAGE-A3 are presented in the context of
HLA Class I–II. If such presentation does not occur due to the lack of
HLA Class I and II expression (like in germ cells or spermatozoid
in the testis), the antigen expressing cells could not be recog-
nized by the MAGE-A3-speciﬁc T-cells that the immunotherapeutic
may  have induced. Similarly to humans, the germ cells of the fetal
gonads are considered immune privileged sites in all animal species
due to the absence of major histocompatibility complex molecules
and are thus protected from immune attack. Nevertheless, potential
toxic effects on the reproductive functions via other mechanisms
as well as potential effects on embryo-fetal development cannot be
excluded.
Therefore, to support the clinical development of the MAGE-
A3 Cancer Immunotherapeutic, we  evaluated the potential toxic
effects induced by injections of the MAGE-A3 Cancer Immunothera-
peutic on embryo-fetal, pre- and post-natal development in female
rats and on male fertility in rats and monkeys. The present studies
did not evaluate the morphology of the germ cells from the fetal
gonads; the assessment of their functionality would have required
the extension of the postnatal period into adulthood up to a mating
trial.
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Fig. 3. Immunohistochemical analysis of MAGE-A3 expression in parafﬁn sections (5 m) of testes from Sprague-Dawley rat (A and B), Cynomolgus monkey (C and D) and
human (E and F) using the rabbit polyclonal antibody TA242 (dilution 1/1000). The antibody was pre-incubated with the human recMAGE-A3 protein (47 g/ml) before use
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dB,  D, F) or it was  not pre-incubated (A, C, E). 20× magniﬁcation.
Treatment with the MAGE-A3 Cancer Immunotherapeutic was
enerally well tolerated; injection site reactions were limited to
wollen areas around the injections sites that were observed in
ome rats following the MAGE-A3 Cancer Immunotherapeutic
njections, although they were also noticed following injections
f AS15 alone. In two other nonclinical safety studies, single or
5 repeated injections of the full human dose of MAGE-A3 Can-
er Immunotherapeutic, respectively, to rabbits or Cynomolgus
onkeys were also well tolerated, although signiﬁcant swelling
as observed in monkeys after multiple injections at the same site
36].
Treatment of female rats with the MAGE-A3 Cancer
mmunotherapeutic or AS15 prior to pairing and during gestation
id not affect female mating performance or fertility, embryo-fetal
evelopment or pre- and post-natal offspring survival or growth upto 25 days of age. However, when comparing the MAGE-A3 Cancer
Immunotherapeutic group and the control group, we observed a
statistically signiﬁcant increase in the litter incidence of persistent
left umbilical artery. However, this minor visceral ﬁnding is of
no toxicological signiﬁcance, occurred in the absence of any
minor or major fetal abnormalities, and was regarded as a normal
variation as the incidence was within the HCD range.
Treatment of male rats with the MAGE-A3 Cancer Immunother-
apeutic or AS15 did not affect reproductive organ weights,
seminology parameters or the macroscopic or microscopic appear-
ance of male reproductive tissues, male mating performance,
fertility or early embryonic development.
Repeated injections of a full human dose of the MAGE-A3 Cancer
Immunotherapeutic had no effect on male fertility in Cynomol-
gus monkeys. In vivo fertility parameters (serum testosterone level,
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emen production and testicular and prostate volumes) were not
ffected. Variations in testosterone levels were observed in all
onkeys throughout the treatment and treatment-free periods and
ere consistent with normal physiological ﬂuctuations [48,49].
Although MAGE-A3 immunohistochemical staining was pre-
iously demonstrated in the testes of both rat and monkey,
istopathology evaluations did not reveal any evidence of toxicity
o the organs of the male reproductive axis. Furthermore, in a pre-
ious toxicology study in Cynomolgus monkeys, histopathological
valuation did not reveal any toxic effects of the MAGE-A3 Cancer
mmunotherapeutic to the female reproductive organs [36].
The MAGE-A3 Cancer Immunotherapeutic was immunogenic
n both rats and monkeys, with all animals developing MAGE-
3-speciﬁc antibodies after 1–5 injections. MAGE-A3-speciﬁc
ntibodies were not detected in the sera of control animals or ani-
als prior to receiving their ﬁrst injection of MAGE-A3 Cancer
mmunotherapeutic (except for one female rat in Study 1 with a
ery low titer). Following 3 or 5 injections of 1/5th of the human
ose of MAGE-A3 Cancer Immunotherapeutic to female or male
ats, respectively, and 8 injections of a full human dose to male
ynomolgus monkeys, all animals showed an induction of anti-
ody response. The timing of the administrations was  chosen to
nsure exposure of the animals (adults, fetuses and pups) to the
peciﬁc antibody response pre-mating and throughout the differ-
nt phases of the embryo-fetal development. These data conﬁrm
hat the MAGE-A3 Cancer Immunotherapeutic is immunogenic in
oth rats and monkeys, in line with observations from the previous
epeated-dose toxicity study in monkeys [36].
The cellular response induced by AS15 has been previously
ssessed in monkeys [36]. In an ex vivo intracellular cytokine stain-
ng assay it was observed that injections of the MAGE-A3 Cancer
mmunotherapeutic induced MAGE-A3 T-cell speciﬁc responses. A
.5- to 8.0-fold increase in the median percentage of CD4+ T cells
roducing IL-2, TNF- or IFN- cytokines was observed compared
o injections of saline. CD8+ T cells producing the same cytokines
ere not detected. AS15 was selected as immunostimulant in the
AGE-A3 Cancer Immunotherapeutic due to its ability to induce
 Th1-biased immune response and because it had the highest
fﬁciency against the growth of MAGE-A3-expressing tumor cells
hen compared to other immunostimulants such as AS01, AS02
r CpG alone [52]. However, it has been previously suggested that
h1 cytokines could be unfavorable to pregnancy outcome [53].
n our study there was no evidence that maternal treatment with
he MAGE-A3 Cancer Immunotherapeutic or AS15 had any adverse
ffect on litter data, as assessed by the pre- and post-implantation
osses.
Taken together, the results of our nonclinical safety studies
ndicate that repeated injections of MAGE-A3 Cancer Immunother-
peutic in rats or monkeys induced immune responses without any
igniﬁcant indication of reproductive toxicity.
. Conclusions
Three to ﬁve injections of 1/5th of a human dose of the MAGE-
3 Cancer Immunotherapeutic in rats or eight injections of a full
uman dose in Cynomolgus monkeys were well tolerated.
Treatment with MAGE-A3 Cancer Immunotherapeutic did not
ffect female rat mating performance or fertility, or embryo-fetal
r pre- and post-natal survival, growth or development of the off-
pring up to 25 days of age, male mating performance (rats) or
ertility parameters (rats and monkeys).Taken together, the ﬁndings from these nonclinical safety
tudies suggest that repeated injections of MAGE-A3 Cancer
mmunotherapeutic in rats or monkeys induced antibody immune
esponses and did not cause any signiﬁcant reproductive toxicity.xicology 51 (2015) 90–105
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